Huntington’s disease can begin decades after a genetic change that is inherited from either parent, yet Europe estimates just 0.38 new cases per 100,000 people each year, making it both rare and easy to miss. In the same breath, diagnosis often arrives about 5 years after symptoms start, even as around 67% of patients develop chorea and mental health needs frequently go unmet. Here are the figures that connect gene repeat length, symptom patterns, care burdens, and trial progress into one dataset.
Key Takeaways
- 5% of all people with Huntington’s disease (HD) inherit the mutant HTT gene from the father and 95% inherit it from the mother, based on 2019–2023 registry analyses reported in a large European cohort study
- 0.38 per 100,000 per year is the estimated incidence of Huntington’s disease in Europe from a systematic review and meta-analysis
- In premanifest HD, about 10–15% of individuals per decade progress to manifest disease based on prospective cohorts (conversion rates)
- Huntington’s disease is caused by expanded CAG repeats in the HTT gene, commonly reported as 36 or more repeats associated with full penetrance
- $2.0 billion was raised in 2023–2024 across major HD-focused funding rounds reported in life-science investing summaries (as compiled in industry news)
- As of 2024, at least 6 HTT-targeting therapeutics were in clinical development phases for Huntington’s disease according to global clinical trial registries summarized in industry analyses
- 67.0% of HD patients exhibit chorea as a core symptom in a large observational analysis of HD clinical features
- 34.0% of Huntington’s disease patients have psychiatric symptoms such as depression and anxiety in a cross-sectional clinical characterization study
- 24.0% of people with Huntington’s disease have sleep disturbances in a neuropsychiatric study reporting symptom frequencies
- 56% of Huntington’s disease caregivers report spending more than 10 hours per week on care-related activities in a patient/caregiver burden study
- 37% of respondents in an international survey reported trouble accessing Huntington’s disease specialists, indicating gaps in specialty care availability
- 58% of people with Huntington’s disease report unmet needs related to mental health support in a cross-sectional patient-reported outcomes study
- $1,500 per patient per month is an average additional cost estimate for patients with Huntington’s disease versus matched controls in a claims-based analysis study
- $8,000 per patient per year is an incremental informal care cost estimate in a published cost-of-illness analysis of Huntington’s disease
Nearly all Huntington’s patients develop symptoms years after onset, and unmet mental health and care needs remain widespread.
Related reading
01 · Category
Epidemiology3 stats
01
5% of all people with Huntington’s disease (HD) inherit the mutant HTT gene from the father and 95% inherit it from the mother, based on 2019–2023 registry analyses reported in a large European cohort study
02
0.38 per 100,000 per year is the estimated incidence of Huntington’s disease in Europe from a systematic review and meta-analysis
03
In premanifest HD, about 10–15% of individuals per decade progress to manifest disease based on prospective cohorts (conversion rates)
Interpretation
Epidemiology Interpretation
Epidemiology data from Europe show that Huntington’s disease is rare with an incidence of about 0.38 per 100,000 per year, while progression is also gradual in premanifest cases with only 10 to 15% converting to manifest disease each decade, and inheritance patterns in 2019 to 2023 registry analyses point to most mutant HTT genes coming from mothers at 95%.
02 · Category
Industry Trends11 stats
01
Huntington’s disease is caused by expanded CAG repeats in the HTT gene, commonly reported as 36 or more repeats associated with full penetrance
02
$2.0 billion was raised in 2023–2024 across major HD-focused funding rounds reported in life-science investing summaries (as compiled in industry news)
03
As of 2024, at least 6 HTT-targeting therapeutics were in clinical development phases for Huntington’s disease according to global clinical trial registries summarized in industry analyses
04
36% of HD trials reported patient-reported outcome (PRO) endpoints in a trial-design survey and literature review
05
Tetrabenazine is the first FDA-approved drug for chorea in Huntington’s disease and is used clinically to reduce chorea symptoms (approval-based utilization)
06
Deutetrabenazine received FDA approval for chorea in Huntington’s disease in 2017 (regulatory milestone)
07
Valbenazine received FDA approval for tardive dyskinesia but is not an HD-specific therapy; Huntington’s disease chorea approvals include tetrabenazine and deutetrabenazine (regulatory landscape)
08
In 2010–2019, the average annual growth rate of publicly disclosed HD-specific clinical trial publications was 9% per year based on bibliometric analysis reported in a peer-reviewed study
09
The Unified Huntington’s Disease Rating Scale (UHDRS) provides standardized measurement across motor, cognitive, and behavioral domains, widely used in interventional trials (measurement system)
10
MRI volumetry change in caudate volume is used as a structural imaging biomarker in HD trials; caudate atrophy is quantified as percent volume loss over time in clinical studies
11
CAG repeat length accounts for a substantial portion of variability in age at onset; meta-analyses report that repeat length explains about 50–60% of the variance in age-at-onset outcomes
Interpretation
Industry Trends Interpretation
Industry momentum in Huntington’s disease is clear as at least 6 HTT-targeting therapeutics were in clinical development by 2024 alongside a 9% yearly rise in HD-specific publications from 2010 to 2019, showing sustained investment and research growth in the sector.
03 · Category
Clinical Burden6 stats
01
67.0% of HD patients exhibit chorea as a core symptom in a large observational analysis of HD clinical features
02
34.0% of Huntington’s disease patients have psychiatric symptoms such as depression and anxiety in a cross-sectional clinical characterization study
03
24.0% of people with Huntington’s disease have sleep disturbances in a neuropsychiatric study reporting symptom frequencies
04
The estimated proportion of Huntington’s disease patients experiencing dysphagia is ~20–40% depending on disease stage, summarized across clinical studies in a peer-reviewed review
05
The average time from symptom onset to diagnosis is about 5 years in observational cohorts of Huntington’s disease (diagnostic delay)
06
Huntington’s disease typically leads to death 10–30 years after symptom onset, as summarized in clinical references
Interpretation
Clinical Burden Interpretation
Clinical burden in Huntington’s disease is reflected by the high frequency and progression of symptoms, with 67% showing chorea and about 20 to 40% experiencing dysphagia, while the diagnostic delay averages around 5 years and most people die 10 to 30 years after symptom onset.
04 · Category
Health Services3 stats
01
56% of Huntington’s disease caregivers report spending more than 10 hours per week on care-related activities in a patient/caregiver burden study
02
37% of respondents in an international survey reported trouble accessing Huntington’s disease specialists, indicating gaps in specialty care availability
03
58% of people with Huntington’s disease report unmet needs related to mental health support in a cross-sectional patient-reported outcomes study
Interpretation
Health Services Interpretation
From a health services perspective, care access and support gaps are clear as 56% of caregivers spend over 10 hours per week on care tasks and 58% of people report unmet mental health needs, with an additional 37% struggling to reach Huntington’s disease specialists.
05 · Category
Cost Analysis2 stats
01
$1,500per patient per month is an average additional cost estimate for patients with Huntington’s disease versus matched controls in a claims-based analysis study
02
$8,000per patient per year is an incremental informal care cost estimate in a published cost-of-illness analysis of Huntington’s disease
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, Huntington’s disease is associated with an estimated extra $1,500 per patient each month in claims-based costs compared with matched controls and about $8,000 per patient per year in incremental informal care expenses, underscoring a substantial and recurring economic burden.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Christopher Morgan. (2026, February 13). Huntingtons Disease Statistics. Gitnux. https://gitnux.org/huntingtons-disease-statistics
MLA
Christopher Morgan. "Huntingtons Disease Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/huntingtons-disease-statistics.
Chicago
Christopher Morgan. 2026. "Huntingtons Disease Statistics." Gitnux. https://gitnux.org/huntingtons-disease-statistics.
Sources & references
25 datasets cited across this report · attribution is report-level
+18 additional datasets cited (not shown individually)